Cardiologists are drawing fresh attention to a simple blood test that may improve how cholesterol risk is assessed. A study published in JAMA suggests that measuring ApoB could give a more precise picture than standard LDL testing alone.
Why ApoB stands out
Traditional lipid panels estimate LDL cholesterol, but that number can be less reliable in people with diabetes, metabolic syndrome, obesity, or high triglycerides. ApoB takes a different approach by counting the particles linked to plaque buildup, offering a direct look at how many harmful lipids are circulating in the blood.
Because each plaque-forming particle carries one ApoB protein, the test can reflect arterial risk more clearly than a calculated LDL value. That makes it especially useful when cholesterol results do not fully match a patient's overall health profile.
What the research suggests
In a computer model of 250,000 U.S. adults at risk for heart disease, researchers compared treatment decisions based on LDL, non-HDL cholesterol, and ApoB. The ApoB-based approach was associated with fewer heart attacks and strokes, longer life expectancy, and lower long-term healthcare costs.
Experts from Northwestern University Feinberg School of Medicine and NewYork-Presbyterian note that ApoB is already available and relatively affordable, even if coverage varies. Updated guidance from the American Heart Association and American College of Cardiology also points toward broader use of the test.
Doctors say ApoB may be most helpful when standard results look inconsistent or when patients are already using cholesterol-lowering medication. In those cases, the test can help fine-tune treatment and reveal whether stronger support is needed.
As precision medicine continues to shape preventive care, ApoB testing could become a more common part of heart-health screening and guide smarter decisions for the future.
